Exclusive Summary

• Boasts dual top-tier GMP certifications (US-FDA, EU-EMA) and MAs in France and Germany, providing distributors with robust quality endorsement and minimal regulatory risk for global expansion.
• Perfectly timed for the Rivaroxaban global patent cliff (expiring ~2024 in many regions), enabling distributors to rapidly capture market share in a multi-billion-dollar brand-replacement wave.
• Offers full core strengths (10mg, 15mg, 20mg) to seamlessly cover all primary indications corresponding to first-line therapeutic guideline requirements for AFib and VTE.
• Leverages China's advanced manufacturing scale and supply chain integration to deliver highly competitive pricing alongside premium EU/US quality, maximizing win rates in global tenders.